Categories
Change Password!
Reset Password!
This study evaluated whether the addition of nimesulide (nonsteroidal anti-inflammatory drug; NSAID) to standard metformin (selective cyclooxygenase-2 inhibitor) yields enhanced anti-inflammatory benefits in polycystic ovary syndrome (PCOS).
Metformin + nimesulide demonstrates synergistic anti-inflammatory effects, improving inflammatory biomarkers in PCOS.
This study evaluated whether the addition of nimesulide (nonsteroidal anti-inflammatory drug; NSAID) to standard metformin (selective cyclooxygenase-2 inhibitor) yields enhanced anti-inflammatory benefits in polycystic ovary syndrome (PCOS).
In this prospective, non-randomized controlled study, 100 women with PCOS from hospital-based and outpatient clinics were enrolled. Volunteers were allocated to either metformin alone (n=50) or metformin + nimesulide (n=50) for 3 weeks, with adherence supported through follow-ups. Primary outcomes were alteration in inflammatory markers [interleukin-6 (IL-6) and c-reactive protein/high-sensitivity c-reactive protein (CRP/hs-CRP)], while safety focused on gastrointestinal and hepatic adverse events.
Both metformin monotherapy and combination therapy substantially lowered IL-6 and CRP levels. Notably, metformin + nimesulide aroused substantially greater reduction in CRP levels (p < 0.001), while IL-6 reductions were similar between groups. Multivariate regression analysis revealed total cholesterol and free testosterone as independent predictors of persistent IL-6 levels (R2= 0.516).
Combining metformin with nimesulide markedly lowered CRP levels and boosted anti-inflammatory effects, highlighting a synergistic approach for mitigating inflammation in PCOS.
Academia Open
Nimesulide with Metformin Lowers Inflammatory Markers in Women with PCOS
Reyam Mohammed Qasim et al.
Comments (0)